Cyclerion Therapeutics Inc CYCN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/07/21 EDT
2.77quote price arrow up+0.01 (+0.36%)
Volume
43,026
Close
2.76quote price arrow up+0.27 (+10.84%)
Volume
6,340,887
52 week range
2.08 - 8.96

...

Loading . . .
  • Open2.73
  • Day High3.30
  • Day Low2.68
  • Prev Close2.49
  • 52 Week High8.96
  • 52 Week High Date09/18/20
  • 52 Week Low2.08
  • 52 Week Low Date05/03/21

Key Stats

  • Market Cap94.20M
  • Shares Out34.13M
  • 10 Day Average Volume0.73M
  • Dividend-
  • Dividend Yield-
  • Beta1.81
  • YTD % Change-9.8

KEY STATS

  • Open2.73
  • Day High3.30
  • Day Low2.68
  • Prev Close2.49
  • 52 Week High8.96
  • 52 Week High Date09/18/20
  • 52 Week Low2.08
  • 52 Week Low Date05/03/21
  • Market Cap94.20M
  • Shares Out34.13M
  • 10 Day Average Volume0.73M
  • Dividend-
  • Dividend Yield-
  • Beta1.81
  • YTD % Change-9.8

RATIOS/PROFITABILITY

  • EPS (TTM)-2.22
  • P/E (TTM)-1.24
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-72.226M
  • ROE (MRQ)-109.21%
  • Revenue (MRQ)1.34M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-5,280.73%
  • Debt To Equity (MRQ)7.25%

EVENTS

  • Earnings Date05/21/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Cyclerion Therapeutics Inc

There is no recent news for this security.

Latest From Our Partners

Profile

MORE
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell...
Marsha Fanucci
Chairman
Peter Hecht Ph.D.
Chief Executive Officer
Mark Currie Ph.D.
President
Cheryl Gault
Chief Operating Officer
Anjeza Gjino
Chief Financial Officer
Address
155 Federal Street, Suite 700
Boston, MA
02110-1727
United States